About
Science
Overview
Product Candidates
PRMT5
Overview
PRT811
PRT543
MCL1
Overview
PRT1419
CDK9
Overview
PRT2527
Discovery Engine
Overview
PRT-SCA2 (SMARCA2)
PRT3645 (CDK4/6)
Publications
Clinical Trials
Overview
PRT543 Trials
PRT811 Trials
PRT1419 Trials
PRT2527 Trials
Investors
Overview
News & Events
News Releases
Events & Presentations
Financials
SEC Filings
Quarterly Results
Stock Information
Stock Quote & Chart
Analysts
Governance
Governance Documents
Leadership
Committee Composition
Investor Resources
Investor Faqs
Contact IR
Email Alerts
News
Careers
Contact
Science
About
Science
Overview
Product Candidates
PRMT5
Overview
PRT811
PRT543
MCL1
Overview
PRT1419
CDK9
Overview
PRT2527
Discovery Engine
Overview
PRT-SCA2 (SMARCA2)
PRT3645 (CDK4/6)
Publications
Clinical Trials
Overview
PRT543 Trials
PRT811 Trials
PRT1419 Trials
PRT2527 Trials
Investors
Overview
News & Events
News Releases
Events & Presentations
Financials
SEC Filings
Quarterly Results
Stock Information
Stock Quote & Chart
Analysts
Governance
Governance Documents
Leadership
Committee Composition
Investor Resources
Investor Faqs
Contact IR
Email Alerts
News
Careers
Contact
CDK9
PRT2527 is designed to be a potent and selective CDK9 inhibitor.
'
About
Science
Overview
Product Candidates
PRMT5
Overview
PRT811
PRT543
MCL1
Overview
PRT1419
CDK9
Overview
PRT2527
Discovery Engine
Overview
PRT-SCA2 (SMARCA2)
PRT3645 (CDK4/6)
Publications
Clinical Trials
Overview
PRT543 Trials
PRT811 Trials
PRT1419 Trials
PRT2527 Trials
Investors
Overview
News & Events
News Releases
Events & Presentations
Financials
SEC Filings
Quarterly Results
Stock Information
Stock Quote & Chart
Analysts
Governance
Governance Documents
Leadership
Committee Composition
Investor Resources
Investor Faqs
Contact IR
Email Alerts
News
Careers
Contact
'